Premature Ejaculation Treatment from UK-Registered Doctors

Premature ejaculation is classified by the International Society for Sexual Medicine as ejaculation that always or nearly always occurs within approximately one minute of vaginal penetration (lifelong PE) or within approximately three minutes (acquired PE), combined with an inability to delay ejaculation and negative personal consequences such as distress or avoidance of intimacy.

The condition is broadly divided into two categories.

Lifelong (primary) PE has been present from the first sexual experiences and is believed to have a strong neurobiological basis, involving altered serotonin receptor sensitivity in the ejaculatory pathway.

Men with lifelong PE typically ejaculate within 30-60 seconds of penetration.

Acquired (secondary) PE develops after a period of normal ejaculatory control and may be triggered by psychological factors, relationship changes, prostate inflammation, thyroid dysfunction, or the onset of erectile difficulties.

Prevalence surveys consistently report that 20-30% of men experience PE, making it the most common male sexual dysfunction worldwide.

Despite this, fewer than 10% of affected men seek medical treatment, largely due to embarrassment and a mistaken belief that nothing can be done.

The ejaculatory reflex involves a spinal cord generator modulated by serotonergic pathways descending from the brainstem.

Low serotonin activity at the 5-HT2C receptor and hypersensitivity at the 5-HT1A receptor are implicated in lifelong PE.

This neurochemical model explains why selective serotonin reuptake inhibitors are effective treatments.

Risk factors and associations include:

• Anxiety and depression (odds ratio 2.5-3.0)
• Comorbid erectile dysfunction (40% of men with ED also report PE)
• Prostatitis (chronic pelvic pain syndrome)
• Hyperthyroidism (normalising thyroid function improves PE in 50% of cases)
• Low frequency of sexual activity

Dapoxetine (Priligy) is the only medication specifically developed and MHRA-licensed for on-demand treatment of premature ejaculation.

It is a short-acting selective serotonin reuptake inhibitor (SSRI) with a rapid onset (Tmax 1-2 hours) and fast elimination (half-life 1.

4 hours), making it suitable for as-needed dosing rather than daily use.

The recommended starting dose is 30 mg, taken 1-3 hours before anticipated sexual activity. If the response is insufficient and side effects are tolerable, the dose may be increased to 60 mg.

Clinical trials demonstrate that dapoxetine 30 mg increases mean intravaginal ejaculatory latency time (IELT) from a baseline of 0.9 minutes to 3.0 minutes, while the 60 mg dose extends it to 3.

5 minutes. Patient-reported control over ejaculation improves in approximately 70% of users.

Common side effects include nausea (11-22%), dizziness (5-11%), headache (6-9%), and diarrhoea (3-7%). These are generally mild and diminish with continued use.

An orthostatic hypotension test is recommended before prescribing: patients should be warned about dizziness on standing and advised to stay hydrated.

Off-label SSRIs — paroxetine (20 mg daily), sertraline (50-100 mg daily), and fluoxetine (20-40 mg daily) — used continuously rather than on-demand, produce greater IELT improvements (8-12 fold increase with paroxetine) but carry the burden of daily dosing and broader SSRI side effects including reduced libido and weight gain.

Topical anaesthetics provide a non-systemic alternative.

Lidocaine-prilocaine spray (Fortacin/EMLA) applied to the glans 5 minutes before intercourse reduces penile sensitivity and extends IELT by 6-8 fold in clinical studies.

Condom use is advised to prevent transfer to the partner.

Tramadol 50 mg on-demand has shown efficacy in several trials but carries addiction risk and is not routinely recommended in UK practice.

Behavioural techniques have been used to treat PE since Masters and Johnson published their seminal work in 1970.

While pharmacotherapy offers faster results, behavioural methods build lasting ejaculatory control skills and address the psychological dimension of the condition.

The stop-start technique involves stimulating the penis until the point of ejaculatory inevitability, then ceasing stimulation until the arousal subsides, and repeating the cycle 3-4 times before allowing ejaculation.

Practised regularly over 4-8 weeks, this method trains the nervous system to tolerate higher levels of arousal without triggering the ejaculatory reflex.

The squeeze technique adds manual compression of the glans or frenulum at the point of near-ejaculation, which rapidly reduces arousal.

Both techniques can be practised during masturbation initially and then incorporated into partnered activity.

Cognitive behavioural therapy (CBT) addresses the anxiety, catastrophic thinking, and performance pressure that perpetuate PE.

A typical programme runs 8-12 sessions and has demonstrated sustained improvement in 60% of men at 12-month follow-up.

• Identifying and challenging negative automatic thoughts about sexual performance
• Gradual exposure to anxiety-provoking sexual scenarios
• Mindfulness-based arousal awareness training
• Communication skills for discussing sexual needs with a partner

Combination therapy — pharmacological plus behavioural — consistently outperforms either approach alone.

A randomised controlled trial published in the Journal of Urology found that dapoxetine plus behavioural intervention produced a 5.7-fold IELT increase versus 3.2-fold with dapoxetine alone.

Pelvic floor rehabilitation is an emerging approach.

Strengthening the bulbocavernosus muscle through targeted exercises has shown benefit in small studies, with 82% of participants gaining better control after 12 weeks of physiotherapist-guided training.

Partner involvement significantly improves outcomes. Couples-based therapy reduces performance anxiety, improves communication, and increases relationship satisfaction alongside the sexual benefits.

An accurate diagnosis of PE begins with a detailed sexual history.

The clinician needs to establish the duration of the problem (lifelong versus acquired), the estimated intravaginal ejaculatory latency time, the degree of perceived control, and the level of distress experienced by both the patient and their partner.

The Premature Ejaculation Diagnostic Tool (PEDT) is a validated 5-item questionnaire that helps standardise the assessment. Scores of 11 or above indicate PE with high sensitivity and specificity.

The tool covers frequency of premature ejaculation, perceived control, distress, interpersonal difficulty, and whether ejaculation occurs with minimal stimulation.

Physical examination is generally focused on excluding comorbid conditions. Genital examination checks for phimosis, frenulum breve, or signs of prostatitis.

Digital rectal examination may be indicated in men with acquired PE and lower urinary tract symptoms.

Investigations are guided by clinical suspicion:

• Thyroid function tests (TSH, free T4) — hyperthyroidism is found in 50% of men with acquired PE in some studies
• Prostate-specific antigen if prostatitis is suspected
• Testosterone levels if low libido or erectile dysfunction coexists
• Fasting glucose and HbA1c in men with vascular risk factors

Differential diagnosis includes:

• Erectile dysfunction masquerading as PE (men rush to ejaculate before losing their erection)
• Natural variation in ejaculatory latency (IELT 3-7 minutes is within the normal range)
• Situational PE occurring only with certain partners or in specific circumstances
• Medication-induced delayed ejaculation being perceived as "normal" by a partner

A thorough assessment ensures the correct diagnosis and avoids unnecessary treatment.

In acquired PE particularly, addressing the underlying cause (thyroid correction, prostatitis treatment, ED management) may resolve the ejaculatory problem without specific PE therapy.

Most men with premature ejaculation can be effectively managed through primary care or an online prescribing service.

However, certain clinical scenarios benefit from referral to a urologist or psychosexual medicine specialist.

Referral is advisable when:

• PE persists despite adequate trials of dapoxetine at 60 mg and behavioural therapy over 3-6 months
• Acquired PE is accompanied by pelvic pain, urinary symptoms, or signs of prostatitis requiring urological investigation
• There is significant comorbid erectile dysfunction that complicates the clinical picture
• Psychological distress is severe, including depression, suicidal ideation, or relationship breakdown requiring specialist psychosexual intervention
• The patient has contraindications to all standard pharmacological treatments

Specialist centres can offer treatments not available through primary care, including:

• Intracavernosal injections for combined ED-PE presentations
• Selective dorsal neurectomy (surgical reduction of penile sensation) — performed rarely and only after exhaustive conservative management
• Intensive psychosexual therapy programmes, typically 12-20 sessions
• Clinical trial access for emerging treatments such as novel serotonergic agents

Self-help resources should not be overlooked. The British Association for Sexual Health and HIV (BASHH) and the Sexual Advice Association provide evidence-based patient information.

Many men find that understanding the condition reduces anxiety, which itself improves control.

Partners should be encouraged to attend consultations where possible.

PE affects the couple, not just the individual, and collaborative management produces the most durable improvements in both ejaculatory control and relationship satisfaction.

Treatment is typically reviewed after 4-6 weeks for pharmacological approaches and 8-12 weeks for behavioural programmes.

Long-term use of dapoxetine has been studied for up to two years with sustained efficacy and no evidence of tolerance or dependency.